Cargando…
Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) remains a life-limiting condition with a major impact on the ability to lead a normal life. Although existing therapies may improve the outlook in some patients there remains a major unmet need to develop more effective therapies in this condition. There have be...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641734/ https://www.ncbi.nlm.nih.gov/pubmed/23662201 http://dx.doi.org/10.4103/2045-8932.109940 |
_version_ | 1782268052370358272 |
---|---|
author | Morrell, Nicholas W. Archer, Stephen L. DeFelice, Albert Evans, Steven Fiszman, Monica Martin, Thomas Saulnier, Muriel Rabinovitch, Marlene Schermuly, Ralph Stewart, Duncan Truebel, Hubert Walker, Gennyne Stenmark, Kurt R. |
author_facet | Morrell, Nicholas W. Archer, Stephen L. DeFelice, Albert Evans, Steven Fiszman, Monica Martin, Thomas Saulnier, Muriel Rabinovitch, Marlene Schermuly, Ralph Stewart, Duncan Truebel, Hubert Walker, Gennyne Stenmark, Kurt R. |
author_sort | Morrell, Nicholas W. |
collection | PubMed |
description | Pulmonary arterial hypertension (PAH) remains a life-limiting condition with a major impact on the ability to lead a normal life. Although existing therapies may improve the outlook in some patients there remains a major unmet need to develop more effective therapies in this condition. There have been significant advances in our understanding of the genetic, cell and molecular basis of PAH over the last few years. This research has identified important new targets that could be explored as potential therapies for PAH. In this review we discuss whether further exploitation of vasoactive agents could bring additional benefits over existing approaches. Approaches to enhance smooth muscle cell apotosis and the potential of receptor tyrosine kinase inhibition are summarised. We evaluate the role of inflammation, epigenetic changes and altered glycolytic metabolism as potential targets for therapy, and whether inherited genetic mutations in PAH have revealed druggable targets. The potential of cell based therapies and gene therapy are also discussed. Potential candidate pathways that could be explored in the context of experimental medicine are identified. |
format | Online Article Text |
id | pubmed-3641734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-36417342013-05-09 Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension Morrell, Nicholas W. Archer, Stephen L. DeFelice, Albert Evans, Steven Fiszman, Monica Martin, Thomas Saulnier, Muriel Rabinovitch, Marlene Schermuly, Ralph Stewart, Duncan Truebel, Hubert Walker, Gennyne Stenmark, Kurt R. Pulm Circ Pulmonary Hypertension–Academic Research Consortium: Anticipated Classes of New Medications and Molecular Targets Pulmonary arterial hypertension (PAH) remains a life-limiting condition with a major impact on the ability to lead a normal life. Although existing therapies may improve the outlook in some patients there remains a major unmet need to develop more effective therapies in this condition. There have been significant advances in our understanding of the genetic, cell and molecular basis of PAH over the last few years. This research has identified important new targets that could be explored as potential therapies for PAH. In this review we discuss whether further exploitation of vasoactive agents could bring additional benefits over existing approaches. Approaches to enhance smooth muscle cell apotosis and the potential of receptor tyrosine kinase inhibition are summarised. We evaluate the role of inflammation, epigenetic changes and altered glycolytic metabolism as potential targets for therapy, and whether inherited genetic mutations in PAH have revealed druggable targets. The potential of cell based therapies and gene therapy are also discussed. Potential candidate pathways that could be explored in the context of experimental medicine are identified. Medknow Publications 2013 /pmc/articles/PMC3641734/ /pubmed/23662201 http://dx.doi.org/10.4103/2045-8932.109940 Text en Copyright: © Pulmonary Circulation http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Pulmonary Hypertension–Academic Research Consortium: Anticipated Classes of New Medications and Molecular Targets Morrell, Nicholas W. Archer, Stephen L. DeFelice, Albert Evans, Steven Fiszman, Monica Martin, Thomas Saulnier, Muriel Rabinovitch, Marlene Schermuly, Ralph Stewart, Duncan Truebel, Hubert Walker, Gennyne Stenmark, Kurt R. Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension |
title | Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension |
title_full | Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension |
title_fullStr | Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension |
title_full_unstemmed | Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension |
title_short | Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension |
title_sort | anticipated classes of new medications and molecular targets for pulmonary arterial hypertension |
topic | Pulmonary Hypertension–Academic Research Consortium: Anticipated Classes of New Medications and Molecular Targets |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641734/ https://www.ncbi.nlm.nih.gov/pubmed/23662201 http://dx.doi.org/10.4103/2045-8932.109940 |
work_keys_str_mv | AT morrellnicholasw anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT archerstephenl anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT defelicealbert anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT evanssteven anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT fiszmanmonica anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT martinthomas anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT saulniermuriel anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT rabinovitchmarlene anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT schermulyralph anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT stewartduncan anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT truebelhubert anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT walkergennyne anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension AT stenmarkkurtr anticipatedclassesofnewmedicationsandmoleculartargetsforpulmonaryarterialhypertension |